Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden.
(2011) In Primary Care Diabetes 5. p.89-94- Abstract
- AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice. METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented. RESULTS: During the course of the study, 1154 patients were included (age range 20-95years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol)... (More)
- AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice. METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented. RESULTS: During the course of the study, 1154 patients were included (age range 20-95years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per patient year. Major hypoglycaemic events were rare (two in total). CONCLUSIONS: BIAsp 30 was initiated safely and effectively in insulin-naïve patients with T2DM. The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1883404
- author
- Berntorp, Kerstin LU ; Haglund, Mattias ; Sjövall Larsen, Sara ; Petruckevitch, Ann and Landin-Olsson, Mona LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Primary Care Diabetes
- volume
- 5
- pages
- 89 - 94
- publisher
- Elsevier
- external identifiers
-
- wos:000304279500004
- pmid:21440523
- scopus:79958858255
- pmid:21440523
- ISSN
- 1878-0210
- DOI
- 10.1016/j.pcd.2011.02.003
- language
- English
- LU publication?
- yes
- id
- 38dbfdd3-cace-4b15-b000-55bfe380ed14 (old id 1883404)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21440523?dopt=Abstract
- date added to LUP
- 2016-04-04 07:27:16
- date last changed
- 2024-05-10 21:45:29
@article{38dbfdd3-cace-4b15-b000-55bfe380ed14, abstract = {{AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice. METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented. RESULTS: During the course of the study, 1154 patients were included (age range 20-95years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per patient year. Major hypoglycaemic events were rare (two in total). CONCLUSIONS: BIAsp 30 was initiated safely and effectively in insulin-naïve patients with T2DM. The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden.}}, author = {{Berntorp, Kerstin and Haglund, Mattias and Sjövall Larsen, Sara and Petruckevitch, Ann and Landin-Olsson, Mona}}, issn = {{1878-0210}}, language = {{eng}}, pages = {{89--94}}, publisher = {{Elsevier}}, series = {{Primary Care Diabetes}}, title = {{Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden.}}, url = {{http://dx.doi.org/10.1016/j.pcd.2011.02.003}}, doi = {{10.1016/j.pcd.2011.02.003}}, volume = {{5}}, year = {{2011}}, }